Pharmaceutical formulations of nitrite and uses thereof

Patent metadata

Field	Value
Publication number	US-11247902-B2
Application number	US-201716307739-A
Country	US
Kind code	B2
Filing date	Jun 6, 2017
Priority date	Jun 6, 2016
Publication date	Feb 15, 2022
Grant date	Feb 15, 2022

Abstract

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

First claim

The invention claimed is:

1. A method of improving nerve conduction velocity in a patient identified as being in need of improved nerve conduction velocity, the method comprising:
administering between 60 mg and 100 mg of inorganic nitrite or a pharmaceutically acceptable salt thereof twice daily to the patient for a treatment period sufficient to improve nerve conduction velocity in the patient.

2. The method of claim 1 , further comprising monitoring whether there is an increase in nerve conduction velocity in the patient.

3. The method of claim 2 , wherein the monitoring is performed by using a nerve conduction velocity test or a sensory test.

4. The method of claim 1 , wherein there is an increase in nerve conduction velocity after administration of the inorganic nitrite or the pharmaceutically acceptable salt.

5. The method of claim 4 , wherein the increase in nerve conduction velocity is one 1 m/s, 1.5 m/s, 2 m/s, 2.5 m/s, 3 m/s, 3.5 m/s, 4 m/s, 4.5 m/s, 5 m/s, 5.5 m/s, 6 m/s, 6.5 m/s or between 1 m/s and 7 m/s relative to the nerve conduction velocity of the patient prior to administration of the inorganic nitrite or the pharmaceutically acceptable salt.

6. The method of claim 1 , wherein the patient exhibits an increased ability to sense a monofilament after administration of the inorganic nitrite or the pharmaceutically acceptable salt.

7. The method of claim 1 , wherein the patient has a microvascular disease.

8. The method of claim 7 , wherein the microvascular disease is selected from the group consisting of diabetic neuropathy, peripheral artery disease, scleroderma, Raynaud's disease, cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy, thrombotic microangiopathy, and thromboangiitis obliterans.

9. The method of claim 8 , further comprising determining whether the patient experiences an improvement in one or more symptoms of the microvascular disease.

10. The method of claim 9 , wherein the patient experiences an improvement in one or more symptoms of the microvascular disease after administration of the inorganic nitrite or the pharmaceutically acceptable salt.

11. The method of claim 1 , wherein the patient does not have pain associated with a microvascular disease.

12. The method of claim 1 , wherein the inorganic nitrite one of is NaNO 2 , KNO 2 , or Ca(NO 2 ) 2 .

13. The method of claim 1 , wherein the inorganic nitrite is NaNO 2 .

14. The method of claim 1 , wherein the inorganic nitrite or the pharmaceutically acceptable salt thereof is administered in a tablet or a capsule.

15. The method of claim 14 , wherein the inorganic nitrite or the pharmaceutically acceptable salt thereof is administered in a sustained release formulation.

16. The method of claim 1 , wherein the inorganic nitrite or the pharmaceutically acceptable salt is administered with one or more pharmaceutically acceptable excipients.

17. The method of claim 1 , wherein the treatment period is at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 11 weeks, at least 12 weeks, at least 13 weeks, or at least 14 weeks or longer.

18. The method of claim 1 , wherein the inorganic nitrite or the pharmaceutically acceptable salt thereof is administered twice daily in a dosage of between 70 mg to 90 mg.

19. The method of claim 18 , wherein the inorganic nitrite or the pharmaceutically acceptable salt thereof is administered twice daily in a dosage of about 70 mg, about 75 mg, about 80 mg, 85 mg, or about 90 mg.

20. The method of claim 1 , wherein the patient is a human.

Assignees

• Univ Louisiana State

Inventors

• Soin Amol
• Kevil Christopher
• Chan Kyle
• Giordano Anthony

Classifications

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K31/381

  having five-membered rings · CPC title

• A61K31/095

  Sulfur, selenium, or tellurium compounds, e.g. thiols · CPC title

• C01B21/50 Primary

  Nitrous acid; Salts thereof · CPC title